PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27162022-5	2016	Resveratrol cotreatment resulted inhibition of testicular cytochrome P4501A1 (CYP1A1) expression, which is the major B(a)P metabolizing agent for BPDE-DNA adduct formation.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	146-150	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	58-76	
27162022-5	2016	Resveratrol cotreatment resulted inhibition of testicular cytochrome P4501A1 (CYP1A1) expression, which is the major B(a)P metabolizing agent for BPDE-DNA adduct formation.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	146-150	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	78-84	
27162022-8	2016	Our findings cumulatively suggest that resveratrol inhibits conversion of B(a)P into BPDE by modulating the transcriptional regulation of CYP1A1 and acting as an antioxidant thus prevents B(a)P-induced oxidative stress and testicular apoptosis.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	85-89	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	138-144